Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.

Article Details

Citation
Copy to clipboard

Hoda MR, Kramer MW, Merseburger AS, Cronauer MV

Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.

Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28.

PubMed ID
27826989 [ View in PubMed
]
Abstract

INTRODUCTION: Hormone sensitive advanced prostate cancer (PCa) is an incurable disease that is treated with a variety of hormonal therapies targeting the androgen/androgen receptor signaling axis. For decades androgen deprivation therapy (ADT) by surgical or chemical castration is the gold standard for the treatment of advanced PCa. Areas covered: This review discusses the pharmacological features of Leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonists/analog and the most commonly used drug in ADT. Expert opinion: Although Leuprolide has been on the market for more than 30 years it is still the leading option for ADT and serves as a basis for most multimodal therapy concepts. The fact that with the onset of castration-resistance in late stage metastatic disease, a prolongation of ADT in combination with a second line hormonal manipulation is recommended supports the importance of the compound for daily clinical practice.

DrugBank Data that Cites this Article

Drugs